SCHEMBL5037796

SCHEMBL5037796

CO[C@H](C(=O)NCc1ccc(C#N)cc1)c1ccc(O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.56
SLC1A3 P43003 1/20 0.47
SLC1A2 P43004 1/20 0.47
EPHX2 P34913 2/20 0.44
LMNA P02545 1/20 0.44
ALDH1A1 P00352 1/20 0.42
LOXL2 Q9Y4K0 1/20 0.42
ESR1 P03372 1/20 0.41
ESR2 Q92731 1/20 0.41
CA12 O43570 1/20 0.40
CA2 P00918 1/20 0.40
CA3 P07451 1/20 0.40
CA6 P23280 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
HIF1A Q16665 1/20 0.40
HTT P42858 1/20 0.40
TSHR P16473 1/20 0.40
MMP2 P08253 1/20 0.39
MMP3 P08254 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5037792 1.00 PKM (0.56) PKMSLC1A3SLC1A2EPHX2LMNA
SCHEMBL5040508 0.89 PKM (0.72) PKMSLC1A3SLC1A2EPHX2LMNA
SCHEMBL5041218 0.89 PKM (0.72) PKMSLC1A3SLC1A2EPHX2LMNA
SCHEMBL5040509 0.89 PKM (0.72) PKMSLC1A3SLC1A2EPHX2LMNA
SCHEMBL5047137 0.87 PKM (0.62) PKMSLC1A3SLC1A2LMNAALDH1A1
SCHEMBL5040915 0.87 PKM (0.53) PKMSLC1A3SLC1A2EPHX2LMNA
SCHEMBL5038062 0.87 PKM (0.53) PKMSLC1A3SLC1A2EPHX2ALDH1A1
SCHEMBL5040908 0.87 PKM (0.53) PKMSLC1A3SLC1A2EPHX2LMNA
SCHEMBL5047139 0.87 PKM (0.62) PKMSLC1A3SLC1A2LMNAALDH1A1
SCHEMBL5038056 0.87 PKM (0.53) PKMSLC1A3SLC1A2EPHX2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567498-B1 MANDELIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-23 EP disclosed
US-7129238-B2 Mandelic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-31 US disclosed
EP-1567498-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-08-31 EP disclosed
US-20040122057-A1 Novel mandelic acid derivatives HOFFMANN-LA ROCHE INC. 2004-06-24 US disclosed
WO-2004048335-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122057-A1 Novel mandelic acid derivatives F7, F11, F9 PKM 4225/4885SLC1A3 2652/4885SLC1A2 2127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.